rafa jodar / Shutterstock.com
19 June 2025NewsAmericasSarah Speight

Regeneron hits Amgen over its blockbuster eye disease treatment

The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 May 2026   Trade secret filings in the US reached an all-time high in 2025—particularly those relating to AI. Jeff Farrow of Michelman Robinson explains the principles that courts are increasingly applying, and how companies on both sides of the ‘v’ can prepare.
Americas
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.
Americas
7 May 2026   A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.